Telix Pharmaceuticals' (ASX:TLX) unaudited revenue for the first quarter reached AU$186 million, an increase of 62% from AU$115 million in the year-ago period, according to a Tuesday filing with the Australian bourse.
This comprised AU$151 million from global sales of Illuccix and AU$33 million from RLS Radiopharmacies, which was acquired in January.
The biopharmaceutical company reaffirmed its FY2025 revenue guidance of AU$770 million to AU$800 million. It noted that this will be updated "at the appropriate time" to take into account reimbursement for Gozellix in the US and Illuccix in ex-US markets, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.